HC Wainwright Reiterates “Buy” Rating for Voyager Therapeutics (NASDAQ:VYGR)

HC Wainwright reissued their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a $30.00 price target on the stock.

Several other research analysts have also commented on the company. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, October 11th. Finally, Wedbush reduced their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.43.

Voyager Therapeutics Price Performance

VYGR opened at $6.75 on Thursday. Voyager Therapeutics has a 12-month low of $5.71 and a 12-month high of $11.72. The stock has a market capitalization of $367.16 million, a PE ratio of -135.00 and a beta of 0.91. The firm’s fifty day moving average price is $6.55 and its 200 day moving average price is $7.61.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. The business had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same quarter in the prior year, the business posted ($0.51) EPS. On average, equities research analysts forecast that Voyager Therapeutics will post -1.27 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC raised its stake in Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after acquiring an additional 528,000 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after purchasing an additional 702,030 shares during the period. Farallon Capital Management LLC raised its stake in shares of Voyager Therapeutics by 77.4% during the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after purchasing an additional 1,000,000 shares in the last quarter. Great Point Partners LLC acquired a new stake in Voyager Therapeutics in the second quarter worth about $12,668,000. Finally, Price T Rowe Associates Inc. MD grew its position in Voyager Therapeutics by 3.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after buying an additional 37,144 shares in the last quarter. 48.03% of the stock is owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.